Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma.
Jelinek T, Adamusova L, Popkova T, Tvrda I, Smejkalova J, Simicek M, Salounova D, Kascak M, Mihalyova J, Plonkova H, Duras J, Navratil M, Hajek R, Koristek Z. Jelinek T, et al. Among authors: duras j. Bone Marrow Transplant. 2019 Jul;54(7):1107-1114. doi: 10.1038/s41409-018-0396-x. Epub 2018 Nov 20. Bone Marrow Transplant. 2019. PMID: 30459429
PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.
Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. Jelinek T, et al. Among authors: duras j. Immunology. 2017 Nov;152(3):357-371. doi: 10.1111/imm.12788. Epub 2017 Aug 4. Immunology. 2017. PMID: 28685821 Free PMC article. Review.
Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Jelinek T, Mihalyova J, Kascak M, Duras J, Popkova T, Benkova K, Richterova P, Plonkova H, Zuchnicka J, Broskevicova L, Huvarova L, Cerna L, Growkova K, Simicek M, Havel M, Gumulec J, Navratil M, Koristek Z, Paiva B, Hajek R. Jelinek T, et al. Among authors: duras j. Am J Hematol. 2019 Jan;94(1):E35-E37. doi: 10.1002/ajh.25331. Epub 2018 Nov 25. Am J Hematol. 2019. PMID: 30370955 Free article. No abstract available.
Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia.
Král Z, Michalka J, Móciková H, Marková J, Sýkorová A, Belada D, Jungová A, Vokurka S, Lukášová M, Procházka V, Ďuraš J, Hájek R, Dušek L, Drgoňa Ľ, Ladická M, Ballová V, Vranovský A. Král Z, et al. Among authors: duras j. J Cancer. 2019 Aug 28;10(21):5041-5048. doi: 10.7150/jca.29308. eCollection 2019. J Cancer. 2019. PMID: 31602255 Free PMC article.
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Vodicka P, Benesova K, Janikova A, Prochazka V, Belada D, Mocikova H, Steinerova K, Duras J, Karban J, Hanackova V, Sykorova A, Obr A, Trneny M. Vodicka P, et al. Among authors: duras j. Eur J Haematol. 2022 Aug;109(2):162-165. doi: 10.1111/ejh.13784. Epub 2022 May 11. Eur J Haematol. 2022. PMID: 35502609 Clinical Trial.
The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL).
Janikova A, Michalka J, Bortlicek Z, Chloupkova R, Campr V, Kopalova N, Klener P, Benesova K, Hamouzova J, Belada D, Prochazka V, Pytlik R, Pirnos J, Duras J, Mocikova H, Trneny M. Janikova A, et al. Among authors: duras j. Ann Hematol. 2020 Jul;99(7):1583-1594. doi: 10.1007/s00277-020-04099-y. Epub 2020 Jun 6. Ann Hematol. 2020. PMID: 32506244
22 results